Drug Profile
Omega-3 fatty acid/rosuvastatin
Alternative Names: HCP-1007; Omega-3/rosuvastatin; Rosuvastatin/omega-3; Rosuvastatin/omega-3 fatty acidLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Hanmi Pharmaceutical
- Class Antihyperlipidaemics; Fluorobenzenes; Omega 3 fatty acids; Pyrimidines; Small molecules; Sulfonamides
- Mechanism of Action HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hyperlipidaemia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Hyperlipidaemia(In volunteers) in South Korea (PO, Capsule)
- 01 Mar 2013 Hanmi Pharmaceutical completes a phase I trial in Healthy volunteers in South Korea (NCT01929070)
- 01 Feb 2013 Hanmi Pharmaceutical initiates enrolment in a phase I trial for Healthy volunteers in South Korea (NCT01929070)